| ORIGINAL ARTICLE |
|
| Year : 2018 | Volume
: 17
| Issue : 1 | Page : 42-46 |
|
|
Intralesional streptomycin: New, safe, and effective therapeutic option for cutaneous leishmaniasis
Wisam Majeed Kattoof
Department of Dermatology, College of Medicine, Mustansiriyah University, Baghdad, Iraq
Correspondence Address:
Dr. Wisam Majeed Kattoof
College of Medicine, Mustansiriyah University, Baghdad
Iraq
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/MJ.MJ_11_18
|
|
|
Background: Leishmaniasis encompasses a spectrum of chronic infections in humans in which organisms are found within phagolysosomes of mononuclear phagocytes. Cutaneous leishmaniasis is divided into Old World and New World cutaneous leishmaniasis caused by Leishmania tropica. Aminoglycosides as it antibacterial, were also tried as a new therapeutic option for parasitic infestation. Proliferation rate and protein synthesis in the promastigote stage of the parasite are inhibited by aminoglycoside such as streptomycin. Aim: The aim of this study is to estimate the effectiveness of intralesional streptomycin as a new antileishmanial agent. Settings and Design: This was a therapeutic trial with controls. Materials and Methods: Sixty three lesions (57.8%) from a total of 109 lesions were treated with intralesional injection of streptomycin after dilution with distilled water (20%) and 46 lesions (42.2%) were used as a control. Statistical Analysis: Statistical Analysis System program and Chi-square test were used. Results: In Group A, clinical cure was achieved in 40 lesions (83.3%). Moderate response was noticed in 8 lesions (16.7%). In Group B, none of the remaining 39 control lesions shows moderate, marked or total clearance degree of response. Only 3 lesions (7.7%) showed a slight degree of response and 1 lesion (2.7%) with mild degree. Conclusion: Intralesional streptomycin solution 20% can be considered as a new effective therapeutic option for cutaneous leishmaniasis. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
